Howard R, Zubko O, Bradley R, et al. - Researchers investigated if the cognitive and functional deterioration in patients with mild Alzheimer disease (AD) could be altered by 24 months of minocycline therapy (Minocycline is anti-inflammatory, protects against the toxic influences of β-amyloid in vitro and in animal models of AD, and represents a credible repurposed treatment candidate). This multicenter study included 544 patients with a diagnosis of mild AD recruited from 32 National Health Service memory clinics within secondary specialist services for individuals with dementia. This investigation was carried out in England and Scotland. Random assignment 1:1:1 of participants was done to receive minocycline (400 mg/d or 200 mg/d) or placebo for 24 months, using a semifactorial design. Findings revealed that the progress of cognitive or functional impairment was not delayed by treating patients with mild AD with minocycline, as observed during a 2-year period. These patients poorly tolerated 400 mg of minocycline.